Under the terms of the agreement, CTS will supply Osteotech with a specific number of whole donors and cortical shafts on a monthly basis based upon periodic forecast requirements and available tissue supply.
This new agreement expires in December 2019 and includes one five-year renewal term and subsequent two-year renewal terms subject to six month cancellation clauses.
Owusu-Akyaw, president and CEO of Osteotech, said: "We are excited to expand our relationship with one of the leading tissue banks in the US. CTS has a commitment to respecting the gift of life to enhance patient outcomes which is wholly in-line with Osteotech's mission to leverage our technology into life-changing biologic products."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index